PainReform Ltd. (PRFX )

Currency in USD Disclaimer
$1.04 -$0.36 (-25.71%)
Closed 11/20/2024
$0.97
$1.15
$0.43
$20.16

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol PRFX
  • Company PainReform Ltd.
  • Price $1.04
  • Changes Percentage -25.71
  • Change -0.36
  • Day Low $0.97
  • Day High $1.15
  • Year High $20.16
  • Year Low $0.43
  • Market Cap $2,315,508
  • Price Avg 50 EMA (D) $0.65
  • Price Avg 200 EMA (D) $4.61
  • Exchange NASDAQ
  • Volume 4,916,682
  • Average Volume 414,944
  • Open $1.05
  • Previous Close $1.4
  • EPS -36.84
  • PE -0.03
  • Earnings Announcement 2024-11-20 12:00:00
  • Shares Outstanding $2,226,450

Company brief: PAINREFORM LTD. (PRFX )

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PRFX Corporation News

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

November 20, 2024 at 1:30 pm ET

globenewswire.com -- TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of es...

Income Statement